Published in final edited form as:

J Clin Psychiatry. 2013 February ; 74(2): 149–155. doi:10.4088/JCP.12m07788.

Prevalence of Attenuated Psychotic Symptoms and their Relationship with DSM-IV Diagnoses in a General Psychiatric Outpatient Clinic

Brandon A. Gaudiano, Ph.D. and

Butler Hospital & Alpert Medical School of Brown University

Mark Zimmerman, M.D.

Rhode Island Hospital & Alpert Medical School of Brown University

Abstract

Objective—Attenuated psychosis syndrome (APS) is being proposed for DSM-5 for those impaired by subthreshold psychotic symptoms that are not better accounted for by another diagnosis and not meeting criteria for a psychotic disorder. The rationale is to identify patients who are at high risk for transition to a psychotic disorder in the near future. However, the potential impact of using this new diagnosis in routine clinical practice settings has not been carefully examined.

Method—We investigated the prevalence rate of endorsing attenuated psychotic experiences (PEs) in a treatment-seeking psychiatric outpatient sample ($n = 1,257$) recruited from June 1997 to June 2002 to identify patients who could potentially meet criteria for APS. Patients completed a self-report measure of psychiatric symptoms and afterward were administered structured clinical interviews.

Results—After excluding those with lifetime DSM-IV psychotic disorders, PEs remained highly prevalent in the sample (28% reported at least one current PE) and rates were similar across all major diagnostic categories. Only 1 patient (0.08%) reported PEs but did not meet criteria for another current DSM disorder; however, this individual endorsed other nonpsychotic symptoms of greater severity. PE endorsement was positively correlated with nearly all other nonpsychotic symptom domains and multivariate analysis showed that general clinical severity predicted endorsement of PEs ($ps < .001$).

Conclusion—We could not identify any patients likely meeting criteria for APS alone in our sample. PEs appear to be common in outpatients and represent nonspecific indicators of psychopathology. Diagnosing APS in the community could result in high rates of false positives or high rates of APS “comorbidity” with other nonpsychotic disorders, leading to the increased use of antipsychotic medications without clear need. Therefore, the clinical utility of adding APS to the diagnostic system remains highly questionable.

Address correspondence to Brandon A. Gaudiano, Butler Hospital, Psychosocial Research Program, 345 Blackstone Boulevard, Providence, RI 02906, Brandon_Gaudiano@brown.edu.

Dr. Gaudiano reports no financial or other relationship relevant to the subject of this article. Dr. Zimmerman reports receiving royalties from Western Psychological Services for the Psychiatric Diagnostic Screening Questionnaire.

Keywords

psychosis; diagnosis; attenuated psychosis syndrome; DSM-5; routine clinical practice

The DSM-5 Psychosis Workgroup has proposed a new diagnosis named “attenuated psychosis syndrome” (APS) to describe individuals who are impaired by attenuated psychotic experiences (PEs) but who do not meet criteria for a current or past psychotic disorder.^{1–3} In addition, these individuals must be distressed, impaired, or treatment-seeking and the symptoms cannot be better explained by another current disorder. The original rationale for the inclusion of APS was the earlier identification of patients who are at risk for transition to a full psychotic disorder in the near future. However, the proposed APS diagnosis has deeply divided clinicians and researchers.^{2–6} Proponents argue the diagnosis would promote further research on psychosis proneness, research shows that PEs predict future transition to psychosis, and patients are distressed by symptoms and thus require treatment.⁷ However, opponents have countered that transition rates are relatively low even in higher risk samples (10–30%), no proven efficacious or safe treatments exist, and the diagnosis would produce unnecessary stigma.⁷

Woods et al.⁸ set out to validate an earlier version of the prodromal criteria for first episode psychosis. They found that prodromal patients were able to be differentiated from normal controls and other clinical groups (e.g., help-seeking controls) on a number of clinical variables and 40% converted to a psychotic illness within 2.5 year follow-up. However, prodromal patients had high rates of comorbidity with other common disorders (e.g., 69% had a mood/anxiety diagnosis). Compared with the findings of Woods et al.⁸, subsequent studies have reported more modest estimates of transition to psychosis ranging from 10–20% in other specialty settings.⁹ Furthermore, the proposed DSM-5 criteria for APS differ from those used in forerunner studies, including restriction to three types of psychotic symptoms with intact reality testing and omission of criteria for schizotypal personality disorder or a family history of psychosis with functional deterioration.³ Also, research increasingly has found that PEs in general are relatively common in clinical and nonclinical samples.^{10–13} Thus, critics have noted that there is little evidence to date to establish APS as a separate illness entity or even a lesser form of psychosis in most cases.³

Wood et al.² recently noted that there is no research to date addressing whether current DSM-IV diagnoses adequately capture those who would meet criteria for APS. Previous research on APS mainly has been collected at specialty, high risk psychosis clinics and thus may overestimate the syndrome’s prevalence and clinical utility.⁹ In initial DSM-5 field trial testing, the reliability of the APS criteria could not be adequately established and thus the diagnosis is now being considered for inclusion in the Appendix denoting the need for further study.¹⁴ At this point, critical data are lacking to specify whether or not the APS diagnosis describes a unique patient population that would fail to be captured by the current DSM-IV system.² It also is critical to understand how the APS criteria overlap with other current psychiatric diagnoses. There is little research on this topic to date, especially in routine clinical practice settings. Thus, the aims of the current study from the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS)¹⁵ project were: 1) to

determine the prevalence of PEs in general psychiatric outpatients, 2) to understand the relationship between PEs and other symptom domains to determine their specificity; and 3) to examine the prevalence and clinical characteristics of those who could potentially meet criteria for APS.

METHOD

Sample

Participants included 1,257 adults presenting for treatment at the outpatient practice of the Rhode Island Hospital Department of Psychiatry. The sample consisted of 781 females (61%) and 476 (39%) males, with a mean age of 37.2 (SD = 12.3). The majority of the sample was White (n = 1,090; 86.7%), followed by Black (n = 54; 4.3%), Portuguese (n = 49; 3.9%), Hispanic (n = 39; 3.1%), other or mixed ethnicities (n = 14; 1.1%), and Asian (n = 11; 0.9%). A total of 46% (n = 584) were married or cohabitating and 67% (n = 838) had a high school degree/equivalency or greater education. The most frequently occurring current Axis I DSM-IV diagnoses in the sample were depressive (n = 835; 66.4%) and anxiety disorders (n = 831; 66.1%).

Measures

The *Psychiatric Diagnostic Screening Questionnaire* (PDSQ)¹⁶ is a 125-item self-report measure to screen for psychiatric diagnoses. Respondents dichotomously rate (presence = “yes” or absence = “no”) symptoms across 15 symptom domains, including major depression, dysthymic disorder, posttraumatic stress, bulimia nervosa, obsessive compulsive, panic, mania, psychosis, agoraphobia, social phobia, alcohol abuse/dependence, drug abuse/dependence, generalized anxiety, somatoform, and hypochondriasis. The PDSQ shows evidence of good internal consistency, test-retest reliability, convergent and discriminant validity, as well as adequate sensitivity and specificity.^{17–21} Gibbons et al.²² reported that the PDSQ 15 symptom categories showed validity by identifying distinct categories of illness. The Psychosis subscale was used in the current study to identify patients who reported PEs over the past two weeks based on 6 items: hallucinations (1 item), general delusions (1 item), paranoia (2 items), control by an external force (1 item), and special powers or abilities (1 item). The internal consistency of the Psychosis subscale in the current study was acceptable (Cronbach’s $\alpha = .65$).

The *Structured Clinical Interview for DSM-IV* (SCID-I)²³ and *Structured Interview for the DSM-IV Personality* (SIDP-IV)²⁴ were used to diagnose current DSM-IV Axis I and II disorders, respectively. However, the full SCID-I and the SIDP-IV borderline and antisocial criteria only were administered to the first 100 patients. The remaining patients were administered the full SCID and SIDP-IV assessments. Additional items were included from the *Schedule for Affective Disorders and Schizophrenia* (SADS).²⁵ Social functioning (past month) was rated from 1 (superior) to 7 (grossly inadequate). Suicidal ideation (past two weeks) was rated from 1 (not at all) to 7 (very extreme). Time out of work (past 5 years) was rated from 1 (virtually no time out of work) to 9 (worked none or practically none). Patients not expected to work (e.g., students, those disabled for medical reasons) were excluded from this analysis. In addition, additional items were assessed as part of the SCID, including

current Global Assessment of Functioning (GAF) based on the diagnostic interviews, number of past psychiatric hospitalizations, and number of past suicide attempts.

Family history of psychiatric diagnoses was based on patient interviews using the *Family History Research Diagnostic Criteria* (FHRDC).²⁶ Diagnoses assessed included psychotic disorders for all of the first-degree relatives of patients in the study.

Procedure

All patients provided informed consent based on procedures approved by the local Institutional Review Board. These data were collected as part of the MIDAS project, which represents an integration of research methods into a community-based outpatient practice affiliated with an academic university.¹⁵ Individuals presenting for an intake appointment were asked to participate in a diagnostic evaluation before meeting with their treating clinician. The practice treats individuals with medical insurance on a fee-for-service basis (including Medicare but not Medicaid). Not all patients presenting to the practice participated in the study, due to patient preference for a less time-consuming standard clinical interview or lack of available diagnosticians. Patients also were excluded from participation due to: 1) being under the age of 18 or 2) having a diagnosis of Mental Retardation or other cognitive disorder (e.g., dementia) because another aim of the project is to study the reliability and validity of self-administered questionnaires. However, no differences on demographic characteristics or self-report symptom questionnaires were observed among patients who did and did not participate in the diagnostic evaluation.^{16, 27}

Patients first completed the self-report PSDQ to screen for PEs and then patients were interviewed using the SCID-I and SIDP-IV to identify the full range of DSM-IV diagnoses, including psychotic disorders. Diagnosticians were trained for a period of 3 months, which included training by the principal investigator (M.Z.), observing at least 5 interviews, and administering 15 to 20 interviews while being observed and supervised. Diagnosticians were then required to demonstrate exact or near-exact reliability with a senior diagnostician for 5 consecutive interviews. Diagnosticians received ongoing supervision. Based on joint-interviews ($n = 65$) conducted over the course of the entire project, interrater reliabilities ranged from $\kappa = .64$ for substance use disorders to $\kappa = 1.0$ for obsessive compulsive and somatoform disorders. Reliability for any personality disorder from 47 joint interviews was $\kappa = 0.90$.

As shown in Table 1, we were able to assess most of the currently proposed criteria for APS.¹ We fully assessed criteria I (characteristic symptoms), V (differential diagnosis), and VI (exclusion of lifetime psychotic disorder). We were able to partially assess criteria II (frequency/currency criterion) and III (distress/disability/treatment seeking criterion). The only criterion we were unable to assess was related to progression (III).

Statistical Analyses

Patients were categorized based on endorsement of at least one PE item from the PDSQ. We defined current psychiatric disorders as meeting full criteria or criteria for partial remission. We also examined correlations among the PDSQ Psychosis and other symptoms subscales.

Patients with versus without PEs were compared on available clinical severity indicators (e.g., GAF) using independent-samples t-tests or chi square tests as appropriate. Finally, a hierarchical logistic regression analysis was conducted to identify the clinical variables that best predicted PE status in multivariate analysis. All tests were two-tailed, and alpha was set a priori at .01 to reduce error due to multiple comparisons.

RESULTS

Prevalence of PEs

We excluded patients diagnosed with current or past DSM-IV psychotic disorders from analyses ($n = 39$; 3.1%). Patients diagnosed with a psychotic disorder had significantly higher scores on the PDSQ Psychosis subscale than those without a psychotic disorder ($t = 8.62$, $df = 1256$, $p < .001$). Of the remaining sample ($n = 1,218$), 28.3% ($n = 345$) endorsed at least one PE over the past two weeks. A total of 12.2% ($n = 149$) endorsed the hallucination-related item and 24.0% ($n = 292$) endorsed at least one of the delusion-related items. A total of 8.1% ($n = 98$) endorsed both hallucination and delusion items concurrently. The mean number of PEs endorsed was 1.7 ($SD = 1.0$; $n = 345$).

Figure 1 depicts the prevalence rates of patients endorsing at least one PE, as well as broken down by endorsement of hallucination versus delusion items. Endorsement of any PEs by diagnostic category were as follows: somatoform disorders (49%), personality disorders (46%), bipolar disorders (45%), eating disorders (39%), impulse control disorders (38%), anxiety disorders (34%), depressive disorders (32%), substance use disorders (31%), and adjustment disorders (7%). As Figure 1 also indicates that for the major disorders, rates of PE delusions (27%–44%) were higher than rates of PE hallucinations (15%–20%) across diagnostic categories.

We found that 2.5% ($n = 31$) of the sample did not endorse any PEs or meet criteria for any current DSM disorder. More importantly, only one patient (0.08%) endorsed PEs but *did not meet criteria* for a current psychiatric disorder based on the SCID-I or SIDP-IV. This one patient endorsed current PEs (2 PDSQ Psychosis items) but did not meet criteria for another current DSM-IV disorder. However, a diagnosis of APS would have been unlikely even in this case because the patient also endorsed 38 other non-PE PDSQ symptoms and had past diagnoses of alcohol dependence and depression NOS. Thus, the APS diagnosis alone could not be applied to any patients in the sample. This prevented us from formally examining specificity of the APS diagnosis in the sample.

Association between PEs and Clinical Severity

Table 2 shows positive correlations between PEs and the other symptom domains on the PDSQ (except for the alcohol abuse/dependence subscale). The PDSQ Psychosis scale was moderately correlated with total PDSQ subscales (minus the Psychosis subscale), $r = .46$, $p < .001$.

Table 3 shows that PE patients were less likely to graduate high school, less likely to be married/cohabitating, more likely to be members of racial/ethnic minorities, and younger in age, ($ps < .01$). Furthermore, patients with PEs demonstrated significantly lower current

GAF scores, poorer current social functioning, more time out of work, more psychiatric hospitalizations, more suicide attempts, higher levels of current suicidal ideation, and higher numbers of current psychiatric diagnoses (all $ps < .01$). There was no significant difference between those with versus without PEs who reported a family history of a psychotic disorder in first-degree relatives ($p = .92$).

Results from the hierarchical regression analysis are shown in Table 4. Demographic variables (age, high school graduate or higher educational level, racial/ethnic minority status, and married/cohabitating) were entered in the first step and clinical variables (Total PDSQ score, GAF, total number of current diagnoses, social functioning, suicidal ideation severity, number of suicide attempts, and number of psychiatric hospitalizations) were added in the second step. In step one ($\chi^2 = 83.24$, $df = 4$, $p < .001$), having lower levels of education and being a member of a racial/ethnic minority predicted PE status ($ps < .01$). The model explained 9.5% of the variance in PE endorsement. In step two ($\chi^2 = 250.51$, $df = 7$, $p < .001$), higher total PDSQ scores, lower GAF, and lower educational attainment predicted PE endorsement ($ps < .01$). The final model explained 34.5% of the variance in PE endorsement, and had a sensitivity of 89.9% but a specificity of 43.8%.

DISCUSSION

Results show that current PEs are common and reported by 28% of general psychiatric outpatients who did not have a lifetime psychotic disorder. This is consistent with research in previous samples showing a high degree of co-occurrence between anxiety and mood disorders and PEs.^{13, 28, 29} Although patients with current PEs were more clinically severe and impaired as reported elsewhere,^{30–33} these symptoms appear best to be viewed as nonspecific indicators of psychopathology that span multiple diagnostic categories. Interestingly, van Nierop et al.³⁴ showed that even individuals with *false-positive* self-reported psychotic symptoms showed greater severity compared with those without self-reported psychotic symptoms. Furthermore, PE endorsement in our sample was associated with higher levels of symptomatology across nearly all diagnostic domains (except alcohol use disorders). Overall, the presence of PEs was best predicted by the total severity of current symptoms and overall level of functional impairment. Most importantly, we could not identify any individuals in our sample of 1,257 patients for whom a diagnosis of APS alone likely would have been made.

In addition to the APS criteria proposed for DSM-5, Woods et al.⁸ defined prodromal risk that included a family history of psychosis and schizotypal personality disorder. However, family history of psychosis did not differentiate those with versus without PEs and no patients in our sample were diagnosed with schizotypal personality disorder and had a family history of psychosis. Therefore, even considering these expanded criteria would not have changed our findings. Other potential criteria have also been proposed for identifying psychosis risk, such as brief but intermittent psychotic symptoms^{35–37} or certain neuropsychological profiles^{38, 39} that require further study.

In addition to absolute prevalence, one must also consider specificity. To illustrate this using another disorder, only 3 patients in our sample were diagnosed with schizophreniform

disorder, but this diagnosis identified a unique population whose symptoms could not be better explained by other diagnoses. Furthermore, the diagnosis did not result in excessive overlap with other common disorders. It is important to note that our data do not demonstrate that patients with APS alone do not theoretically exist in the community. However, they may not be sufficiently disturbed by or have insufficient insight to seek treatment for PEs alone.⁴⁰ Our findings are consistent with other research suggesting that the specificity of PEs is probably quite low.¹²

There are two primary explanations for endorsement of PEs in our sample. First, the presence of PEs for many of patients can be understood to represent nonpsychotic symptoms related to other disorders. For example, patients with social phobia may endorse a paranoia-related item (e.g., “Were you convinced that others were talking about you?”) even though they are not judged to possess a threshold psychotic symptom. Alternately, the DSM-IV currently recognizes several disorders that may be characterized by individual psychotic symptoms. For example, patients with major depression with psychotic features have threshold psychotic symptoms (e.g., hearing voices, paranoia) but only in the context of a depressive episode. Alternately, if we do not consider PE endorsement overlapping with other disorders as false positive cases as some have suggested,⁸ then one must consider that up to 28% of psychiatric outpatients could meet criteria for APS in addition to other comorbid disorders that may be present. However, this would not fit with aim of the APS diagnosis to identify a unique clinical population not meeting criteria for other disorders as indicated by criteria V and IV (see Table 1).²

The critical question for deciding whether to include APS as an official diagnostic entity is whether such signs are necessary and specific to the development of an independent illness. Our findings add to the literature suggesting that primarily defining APS by the presence of attenuated psychotic symptoms (criteria I) is problematic because they lack specificity. Robins and Guze’s⁴¹ classic criteria for developing valid diagnoses indicate that the new clinical population should be clearly differentiated from those with existing diagnoses. The APS criteria did not meet this criterion in our routine clinic setting. Other recent research shows that clinicians are likely to treat APS patients as having a threshold psychotic disorder, even though this is not an accurate understanding of the proposed diagnosis.⁴² An inaccurate diagnosis of psychosis exposes patients to increased stigma, discrimination, and potentially harmful treatments.³ Critics have warned that APS could have the result of establishing a newly diagnosable psychotic-spectrum disorder that would increase the use of treatments (e.g., antipsychotic medications) that lack a favorable risk-benefit profile or even evidence of efficacy in this population.^{3, 7}

One potential limitation is that we did not formally assess criteria for APS in our sample as our data were collected before for they were proposed. Nevertheless, Table 1 shows that we were able to address most of the other criteria. If these attenuated symptoms are common and nonspecific indicators of psychopathology in treatment seeking samples, as the current findings show, then the other criteria are less relevant to understanding the utility of the diagnosis. The only criterion we were not able to assess was related to the timing of PEs (i.e., whether they started or worsened within the past year). However, the logic of this criterion has been questioned.³ For example, it could further increase false positive

diagnoses as many individuals experience transient symptoms that may naturally remit. Alternately, this criterion could increase false negatives as individuals with longer-term PEs (e.g., over 2 years) may be at higher risk for future progression to psychosis but not be captured.

As in the current study, other recent, large-scale studies also have used self-report measures to identify patients with PEs^{10–13, 40, 43, 44} and research attests to their validity for this purpose.⁴⁵ Afterward, patients in our study were administered standardized diagnostic interviews to verify symptoms. However, it would be useful for future research to compare PEs in routine practice settings to those initially screened using clinical interviews.⁴⁶ Furthermore, the PDSQ Psychosis subscale screens for only some potential psychotic symptoms; therefore, the rates of PEs in our sample likely represent conservative estimates.

Previous research suggests that depression and psychotic experiences may represent a prodrome for schizophrenia in some cases.⁴⁷ As this is a cross-sectional study, we are unable to specify which, if any, patients with PEs subsequently met criteria for a psychotic disorder. However, our experience treating these patients subsequently at our clinic does not suggest that a significant number later met criteria for schizophrenia. Furthermore, it is critical to understand the performance of a diagnosis in clinical settings at the time it is given and not just in reference to what it may predict in the future. There has been recent discussion about deemphasizing risk prediction as a rationale for the APS diagnosis given its low predictive validity,³ which makes examination of the performance of APS as a unique diagnostic entity even more critical.

Our sample ranged in age from young adult to elderly. Some may argue that our ability to identify APS might have been more successful if we had examined a younger sample. However, if included in DSM-5, APS would be diagnosable in any age group and thus must be examined in all potential patients. Furthermore, age was not a significant predictor of PE endorsement in our multivariate analysis, and other research suggests that age is not strongly associated with emergence of PEs or prediction of transition.¹³

The general population prevalence rate of subclinical PEs is estimated to be about 5% and up to 90% of these experiences are transitory and dissipate over time.⁴⁸ We found that 28% of nonpsychotic, general psychiatric outpatients self-reported at least one current PE. Using more liberal criteria, a study by Yung et al.¹⁰ found that up to 99% of a sample of nonpsychotic adolescents in a mental health program reported one PE at least “sometimes” in their lifetime. The proposed APS criteria should identify a unique clinical population that otherwise would not be appropriately diagnosable in DSM-IV, which it did not achieve in our sample. Therefore, results of the current study are consistent with other sources of data that would lead us to conclude that the clinical utility of adding APS to the DSM remains highly questionable.

Acknowledgments

The preparation of this manuscript was supported in part by a grant from the National Institute of Mental Health (MH076937) awarded to Dr. Gaudiano.

References

1. DSM-5 Psychosis Workgroup. Attenuated Psychosis Syndrome. 2010. [cited March 5, 2012]; Available from: <http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=412>
2. Woods SW, Walsh BC, Saksa JR, McGlashan TH. The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. *Schizophr Res*. 2010; 123(2–3):199–207. [PubMed: 20832249]
3. Cornblatt, BA.; Correll, CU. A new diagnostic entity in DSM-5?. 2010. [cited March 5, 2012]; Available from: http://www.medscape.com/viewarticle/727682_print
4. Arango C. Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry. *Eur Child Adolesc Psychiatry*. 2011; 20(2):67–70. [PubMed: 21057834]
5. Fusar-Poli P, Yung AR. Should attenuated psychosis syndrome be included in DSM-5? *Lancet*. 2012; 379(9816):591–592. [PubMed: 22340290]
6. Shrivastava A, McGorry PD, Tsuang M, et al. “Attenuated psychotic symptoms syndrome” as a risk syndrome of psychosis, diagnosis in DSM-V: The debate. *Indian J Psychiatry*. 2011; 53(1):57–65. [PubMed: 21431011]
7. Carpenter WT, van Os J. Should attenuated psychosis syndrome be a DSM-5 diagnosis? *Am J Psychiatry*. 2011; 168(5):460–463. [PubMed: 21536700]
8. Woods SW, Addington J, Cadenhead KS, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. *Schizophr Bull*. 2009; 35(5):894–908. [PubMed: 19386578]
9. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? *Schizophr Bull*. 2007; 33(3):673–681. [PubMed: 17404389]
10. Yung AR, Buckby JA, Cotton SM, et al. Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. *Schizophr Bull*. 2006; 32(2):352–359. [PubMed: 16254060]
11. van Os J, Verdoux H, Maurice-Tison S, et al. Self-reported psychosis-like symptoms and the continuum of psychosis. *Soc Psychiatry Psychiatr Epidemiol*. 1999; 34(9):459–463. [PubMed: 10541665]
12. Loewy RL, Johnson JK, Cannon TD. Self-report of attenuated psychotic experiences in a college population. *Schizophr Res*. 2007; 93(1–3):144–151. [PubMed: 17459662]
13. Werbeloff N, Drukker M, Dohrenwend BP, et al. Self-reported Attenuated Psychotic Symptoms as Forerunners of Severe Mental Disorders Later in Life. *Arch Gen Psychiatry*. 2012; 69(5):467–475. [PubMed: 22213772]
14. Maxmen A. Psychosis risk syndrome excluded from DSM-5. *Nature*. 2012 May 9.10.1038/nature.2012.10610
15. Zimmerman, m. Integrating the assessment methods of researchers in routine clinical practice: the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project. In: First, MB., editor. *Standardized evaluation in clinical practice*. Washington, DC: American Psychiatric Association; 2003. p. 29-74.
16. Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. *Arch Gen Psychiatry*. 2001; 58(8):787–794. [PubMed: 11483146]
17. Zimmerman M, Chelminski I. A scale to screen for DSM-IV Axis I disorders in psychiatric out-patients: performance of the Psychiatric Diagnostic Screening Questionnaire. *Psychol Med*. 2006; 36(11):1601–1611. [PubMed: 16834794]
18. Zimmerman M, Chelminski I. Screening for anxiety disorders in depressed patients. *J Psychiatr Res*. 2006; 40(3):267–272. [PubMed: 15893327]
19. Sheeran T, Zimmerman M. Factor structure of the Psychiatric Diagnostic Screening Questionnaire (PDSQ), a screening questionnaire for DSM-IV axis I disorders. *J Behav Ther Exp Psychiatry*. 2004; 35(1):49–55. [PubMed: 15157817]
20. Zimmerman M, Chelminski I, Posternak M. An illustration of how a self-report diagnostic screening scale could improve the internal validity of antidepressant efficacy trials. *J Affect Disord*. 2004; 80(1):79–85. [PubMed: 15094261]

21. Zimmerman M, Sheeran T. Screening for principal versus comorbid conditions in psychiatric outpatients with the Psychiatric Diagnostic Screening Questionnaire. *Psychol Assess.* 2003; 15(1): 110–114. [PubMed: 12674730]
22. Gibbons RD, Rush AJ, Immekus JC. On the psychometric validity of the domains of the PDSQ: an illustration of the bi-factor item response theory model. *J Psychiatr Res.* 2009; 43(4):401–410. [PubMed: 18554611]
23. First, MB.; Spitzer, RL.; Williams, JBW.; Gibbon, M. Structured Clinical Interview for DSM-IV (SCID). Washington, D. C: American Psychiatric Association; 2002.
24. Pfohl, B.; Blum, N.; Zimmerman, M. Structured Interview for DSM-IV Personality: SIDP-IV. Washington, D.C: American Psychiatric Association; 1997.
25. Spitzer, R.; Endicott, J. Schedule for Affective Disorders and Schizophrenia (SADS). 3. New York: Biometric Research, New York State Psychiatric Institute; 1977.
26. Endicott, J.; Andreasen, N.; Spitzer, RL. Family History Research Diagnostic Criteria. New York: Biometric Research, New York State Psychiatric Institute; 1978.
27. Zimmerman M, Mattia JJ. Psychiatric diagnosis in clinical practice: is comorbidity being missed? *Compr Psychiatry.* 1999; 40(3):182–191. [PubMed: 10360612]
28. Svriskis T, Korkeila J, Heinimaa M, et al. Axis-I disorders and vulnerability to psychosis. *Schizophr Res.* 2005; 75(2–3):439–446. [PubMed: 15885535]
29. Rosen JL, Miller TJ, D’Andrea JT, McGlashan TH, Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. *Schizophr Res.* 2006; 85(1–3):124–131. [PubMed: 16650735]
30. Varghese D, Scott J, Welham J, et al. Psychotic-like experiences in major depression and anxiety disorders: a population-based survey in young adults. *Schizophr Bull.* 2011; 37(2):389–393. [PubMed: 19687152]
31. Wigman JT, van Nierop M, Vollebergh WA, et al. Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity—implications for diagnosis and ultra-high risk research. *Schizophr Bull.* 2012; 38(2):247–257. [PubMed: 22258882]
32. Binbay T, Drukker M, Elbi H, et al. Testing the Psychosis Continuum: Differential Impact of Genetic and Nongenetic Risk Factors and Comorbid Psychopathology Across the Entire Spectrum of Psychosis. *Schizophr Bull.* 2011
33. van Rossum I, Dominguez MD, Lieb R, Wittchen HU, van Os J. Affective dysregulation and reality distortion: a 10-year prospective study of their association and clinical relevance. *Schizophr Bull.* 2011; 37(3):561–571. [PubMed: 19793794]
34. van Nierop M, van Os J, Gunther N, et al. Phenotypically continuous with clinical psychosis, discontinuous in need for care: evidence for an extended psychosis phenotype. *Schizophr Bull.* 2012; 38(2):231–238. [PubMed: 21908795]
35. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. *Arch Gen Psychiatry.* 2008; 65(1):28–37. [PubMed: 18180426]
36. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizophr Res.* 2004; 67(2–3):131–142. [PubMed: 14984872]
37. Nelson B, Yuen K, Yung AR. Ultra high risk (UHR) for psychosis criteria: are there different levels of risk for transition to psychosis? *Schizophr Res.* 2011; 125(1):62–68. [PubMed: 21074975]
38. Koutsouleris N, Gaser C, Bottlender R, et al. Use of neuroanatomical pattern regression to predict the structural brain dynamics of vulnerability and transition to psychosis. *Schizophr Res.* 2010; 123(2–3):175–187. [PubMed: 20850276]
39. Koutsouleris N, Patschurek-Kliche K, Scheuerecker J, et al. Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis. *Schizophr Res.* 2010; 123(2–3): 160–174. [PubMed: 20826078]

40. Kaymaz N, Drukker M, Lieb R, et al. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. *Psychol Med*. 2012;1–15.
41. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. *Am J Psychiatry*. 1970; 126(7):983–987. [PubMed: 5409569]
42. Jacobs E, Kline E, Schiffman J. Practitioner perceptions of attenuated psychosis syndrome. *Schizophr Res*. 2011; 131(1–3):24–30. [PubMed: 21764261]
43. Loewy RL, Bearden CE, Johnson JK, Raine A, Cannon TD. The prodromal questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. *Schizophr Res*. 2005; 79(1):117–125. [PubMed: 16276559]
44. Muller M, Vetter S, Buchli-Kammermann J, Stieglitz RD, Stettbacher A, Riecher-Rossler A. The Self-screen-Prodrome as a short screening tool for pre-psychotic states. *Schizophr Res*. 2010; 123(2–3):217–224. [PubMed: 20840886]
45. Kline E, Wilson C, Ereshefsky S, et al. Convergent and discriminant validity of attenuated psychosis screening tools. *Schizophr Res*. 2012; 134(1):49–53. [PubMed: 22036199]
46. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. *Schizophr Bull*. 2003; 29(4):703–715. [PubMed: 14989408]
47. Hafner H, Maurer K, Trendler G, an der Heiden W, Schmidt M. The early course of schizophrenia and depression*. *Eur Arch Psychiatry Clin Neurosci*. 2005; 255(3):167–173. [PubMed: 15995900]
48. van Os J, Linscott RJ, Myin-Germeyns I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. *Psychol Med*. 2009; 39(2):179–195. [PubMed: 18606047]
49. American Psychiatric Association. Attenuated Psychosis Syndrome (Proposed for Section III of DSM-5). 2012. [cited; Available from: <http://www.dsm5.org/proposedRevisions/Pages/proposedrevision.aspx?rid=412#>]

Clinical Points

- Attenuated psychotic experiences, the key feature of the newly proposed Attenuated Psychosis Syndrome (APS) diagnosis, were present in 28% of patients without a formal psychotic disorder and similarly prevalent across major diagnostic categories, including mood and anxiety disorders.
- The APS criteria fail to capture a unique clinical population in routine practice settings, which could lead to a large number of patients receiving a new diagnosis of a comorbid psychotic-spectrum disorder.
- Implementing the APS diagnosis in clinical practice could lead to an increased use of treatments (e.g., antipsychotic medications) that do not have favorable risk-benefit profiles for these patients.

Figure 1.
Prevalence of Endorsement of at Least One Psychotic Experience by Diagnostic Category

Table 1

Criteria for Attenuated Psychosis Syndrome

Proposed DSM-5 Criteria ⁴⁹	Assessed in the Current Study?
I. Characteristic symptoms: at least 1 of the following in attenuated form with intact reality testing, but of sufficient severity and/or frequency that it is not discounted or ignored <ul style="list-style-type: none"> a. Delusions b. Hallucinations c. Disorganized Speech 	Yes
II. Frequency/currency: symptoms present in the past month and occur at an average frequency of at least once per week in past month	Partial: assessed at least one occurrence in past two weeks
III. Progression: symptom must have begun in or significantly worsened in the past year	No
IV. Distress/Disability/Treatment Seeking: symptoms are sufficiently distressing and/or disabling to the patient and/or parent/guardian to lead them to seek treatment	Partial: treatment seeking/distressed but unclear whether specifically for criterion I symptoms
V. Not better explained by another diagnosis	Yes
VI. Never met criteria for a psychotic disorder	Yes

Table 2

Correlations between PEs and Other Symptom Domains

PDSQ Domains	Psychosis Subscale- Total Score	Psychosis Subscale- Hallucination Item	Psychosis Subscale- Delusion Items
Major Depression	0.295 *	0.201 *	0.280 *
Dysthymia	0.215 *	0.150 *	0.202 *
Posttraumatic Stress Disorder	0.288 *	0.215 *	0.265 *
Bulimia	0.178 *	0.146 *	0.157 *
Obsessive Compulsive Disorder	0.390 *	0.253 *	0.376 *
Panic Disorder	0.347 *	0.226 *	0.332 *
Mania	0.288 *	0.216 *	0.265 *
Agoraphobia	0.332 *	0.176 *	0.287 *
Social Phobia	0.292 *	0.176 *	0.287 *
Alcohol Abuse/Dependence	0.057	0.011	0.065
Drug Abuse/Dependence	0.131 *	0.093 *	0.122 *
Generalized Anxiety Disorder	0.246 *	0.185 *	0.226 *
Somatoform	0.226 *	0.156 *	0.214 *
Hypochondriasis	0.264 *	0.175 *	0.252 *
Total (minus Psychosis subscale)	0.463 *	0.309 *	0.441 *

* $p < .01$,

PE = Psychotic Experience, PDSQ = Psychiatric Diagnostic Screening Questionnaire.

Table 3

Comparisons of Patients with versus without PEs on Demographic and Clinical Variables

	PEs	No PEs	Test Statistic
Demographics			
Sex (female)	65.5 (226)	60.9 (532)	$\chi^2 (1) = 2.26^*$
Married/Cohabiting	39.7 (137)	40.1 (438)	$\chi^2 (1) = 10.75^*$
Racial/Ethnic Minority	19.4 (67)	11.1 (97)	$\chi^2 (1) = 14.71^*$
High School Education or Greater	50.4 (174)	73.8 (645)	$\chi^2 (1) = 61.25^*$
Age (years)	35.4 (11.4)	38.0 (12.5)	$t (1215) = 2.51^*$
Clinical Characteristics			
First-Degree Relative with Psychotic Disorder	3.2 (11)	3.4 (29)	$\chi^2 (1) = 0.01$
Total No. Psychiatric Hospitalizations	0.7 (1.2)	0.4 (1.0)	$t (1216) = 3.69^*$
Total No. Suicide Attempts	0.9 (4.0)	0.4 (2.0)	$t (1217) = 2.81^*$
Current Suicidal Ideation	1.4 (1.4)	0.9 (1.2)	$t (1217) = 6.37^*$
Current Social Functioning	3.3 (1.3)	2.9 (1.1)	$t (1216) = 5.54^*$
Work Impairment from Psychiatric Illness ^a	2.9 (2.0)	2.1 (1.5)	$t (1122) = 6.95^*$
Current Global Assessment of Functioning	49.3 (8.6)	56.6 (9.6)	$t (1217) = 12.14^*$
Total No. Diagnoses	4.2 (2.6)	2.7 (2.0)	$t (1217) = 11.11^*$

M (SD) or % (n),

* $p < .01$,

PE = Psychotic Experience.

^aExcluding students or those unable to work for medical reasons.

Table 4

Hierarchical Logistic Regression Predicting PE Endorsement

		B	SE	Wald	p	Exp(B) (95% CI)
Step 1						
	Age	−0.013	0.006	5.20	.023	0.99 (0.98–1.00)
	Race/Ethnicity	0.516	0.180	8.20	.004*	1.68 (1.12–2.38)
	Education	0.992	0.134	54.54	.000*	2.67 (2.01–3.51)
	Marital Status	0.324	0.139	5.43	.002	1.38 (1.05–1.82)
Step 2						
	Age	−0.011	0.007	2.72	.099	0.99 (0.98–1.00)
	Race/Ethnicity	0.318	0.211	2.27	.132	1.37 (0.91–2.08)
	Education	0.679	0.155	19.27	.000*	1.97 (1.46–2.67)
	Marital Status	0.342	0.157	4.78	.029	1.40 (1.04–1.92)
	PDSQ Total	0.049	0.005	101.88	.000*	1.05 (1.04–1.06)
	GAF	−0.048	0.010	22.75	.000*	0.95 (0.95–0.97)
	No. Diagnoses	−0.071	0.042	2.72	.098	0.93 (0.86–1.01)
	No. Hospitalizations	−0.048	0.069	0.47	.492	0.95 (0.83–1.09)
	Current Suicidal Ideation	−0.091	0.064	2.00	.157	0.91 (0.81–1.04)
	No. Suicide Attempts	0.028	0.026	1.16	.282	1.03 (0.98–1.08)
	Current Social Functioning	0.062	0.067	0.86	.354	1.06 (0.93–1.21)

* p < .01.

PE = Psychotic Experience, PDSQ = Psychiatric Diagnostic Screening Questionnaire.